Vyleesi Hair and Skin Changes: What Bremelanotide Does to Your Complexion and Scalp

How Bremelanotide Works: The Melanocortin Connection

Bremelanotide is a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). It binds melanocortin receptors MC1R, MC3R, MC4R, and MC5R with varying affinity. MC4R activation in the hypothalamus is credited for its pro-sexual effects, but MC1R activation in peripheral tissues, specifically keratinocytes, melanocytes, and hair follicle cells, is what drives the skin and hair changes clinicians and patients notice.

Understanding this receptor biology is not optional background. It is the direct reason the FDA label carries a specific hyperpigmentation warning that no other HSDD drug carries.

MC1R: The Skin and Hair Receptor

MC1R is the primary receptor governing cutaneous pigmentation. When alpha-MSH or a synthetic analogue like bremelanotide binds MC1R, it triggers the cAMP-PKA-MITF pathway, which upregulates tyrosinase and increases eumelanin synthesis. Research published in Pigment Cell & Melanoma Research confirms that MC1R is constitutively expressed in follicular melanocytes, explaining why systemic melanocortin agonists can alter both skin tone and hair pigment over time.

MC4R and Vasodilation: Why Flushing Happens

MC4R activation in vascular endothelium and the autonomic nervous system produces transient vasodilation. In RECONNECT, flushing occurred in 40.3% of the bremelanotide group versus 5.9% placebo, with a number needed to harm of approximately 3 for this specific adverse effect. Most episodes lasted under 1 hour. The mechanism overlaps with the transient blood pressure changes also documented in the trial, where systolic BP rose a mean of 2.0 mmHg and diastolic 1.2 mmHg within 12 hours of dosing. The full RECONNECT dataset is indexed at PubMed.

Receptor Distribution in Hair Follicles

Hair follicles are not passive bystanders. The outer root sheath, dermal papilla, and follicular melanocytes all express MC1R. A 2009 review in Experimental Dermatology showed that melanocortin peptides regulate the melanocyte stem cell niche within the hair bulge region. Repeated MC1R stimulation may shift the follicular melanocyte population toward greater eumelanin production, potentially darkening existing hair over months of cumulative dosing.

Flushing: The Most Common Skin Change

Flushing is the dominant skin-related adverse event with bremelanotide. It is not the same as an allergic reaction. The distinction matters clinically because flushing requires different management than urticaria or angioedema.

Incidence and Time Course

In RECONNECT (N=1,267 randomized, published in Obstetrics & Gynecology 2019), flushing was reported by 40.3% of participants receiving bremelanotide 1.75 mg versus 5.9% receiving placebo. The trial is accessible at PubMed PMID 31060191. Episodes typically began within 30 minutes of injection, peaked around 45 to 60 minutes, and resolved spontaneously. Severity was mild to moderate in the majority of cases. Only 4% of participants discontinued the drug due to flushing.

Anatomical Pattern

The flush predominantly involves the face, neck, and upper chest, corresponding to regions with the highest density of melanocortin-responsive cutaneous vasculature. Some participants also report warmth in the palms. This distribution mirrors the niacin-flush pattern, which also operates through a vasodilatory receptor mechanism, though the specific receptor targets differ.

Management Options

Patients can reduce flushing severity by injecting in the abdomen (vs. Thigh or upper arm) and by pre-hydrating adequately. FDA prescribing information for Vyleesi does not recommend prophylactic antihistamines but notes that lying down may help with concurrent nausea. Dose timing, specifically injecting at least 45 minutes before anticipated sexual activity rather than immediately before, gives some protection by allowing the peak vasodilatory response to pass.

Hyperpigmentation: The Labeling Warning You Should Read Closely

The FDA label for bremelanotide carries an explicit warning about focal hyperpigmentation. This is not a rare, theoretical risk. It appeared in clinical trial data and prompted a dedicated section in the prescribing information.

What the FDA Label Says

The Vyleesi label states: "Focal hyperpigmentation of the face, breasts, and gums has been reported. This effect was more common in patients with darker skin tones (Fitzpatrick skin types IV-VI)." The label further notes that hyperpigmentation may persist for weeks or months after stopping treatment, and that the safety of bremelanotide use beyond 24 weeks (8 doses per month maximum) has not been established. The full label is available via FDA AccessData.

Fitzpatrick Skin Type Risk Stratification

The Fitzpatrick scale classifies skin from Type I (always burns, never tans) to Type VI (deeply pigmented, never burns). Individuals with Type IV through VI skin have a higher baseline density of melanocytes and a greater capacity for MC1R-mediated melanogenesis. When bremelanotide repeatedly stimulates MC1R, the melanocyte population in susceptible areas, particularly the face and gingivae, produces excess eumelanin. The resulting patches can resemble melasma clinically, though the triggering mechanism is pharmacological rather than UV-driven.

Sites Affected

Documented sites in trial data and post-marketing reports include:

• Face (malar cheeks, forehead)
• Gums (gingival hyperpigmentation)
• Breasts (areolar darkening)
• Injection sites (rare, localized post-inflammatory pigment shift)

Gingival hyperpigmentation is particularly distinctive. It has been reported with other melanocortin-active compounds, including melanotan II, and follows the same MC1R-driven mechanism in oral mucosal melanocytes. A case series in the Journal of the American Academy of Dermatology documented drug-induced gingival pigmentation patterns consistent with melanocortin agonist exposure.

Cumulative Dose Dependency

The risk appears dose-dependent. Patients using bremelanotide at the maximum recommended frequency of 8 doses per month show a higher prevalence of pigment changes than occasional users. The FDA's 24-week safety boundary is not arbitrary. It reflects the point in the phase 3 dataset beyond which longer-term pigmentation data were not collected. Clinicians prescribing beyond 6 months should monitor pigment changes at each follow-up visit and photograph any areas of concern.

Hair Changes: What the Evidence Does and Does Not Show

Hair-related changes with bremelanotide are less well documented than skin changes, but the biology is credible. No large randomized controlled trial has quantified hair pigment change as a primary endpoint with this drug.

What Has Been Observed

Post-marketing case reports describe hair darkening in some patients with prolonged use. The biological rationale: follicular melanocytes express MC1R, and repeated agonist stimulation during the anagen (active growth) phase may shift pigment from pheomelanin (red/yellow tones) toward eumelanin (dark brown/black). This is the same shift exploited experimentally in afamelanotide (Scenesse), a longer-acting MC1R agonist used in erythropoietic protoporphyria, where a 2016 Lancet study (N=94) reported skin darkening as a class effect.

Hair Loss: Is There a Signal?

There is no established causal link between bremelanotide and alopecia. The drug does not suppress androgens or interact with 5-alpha reductase. The FDA adverse event reporting system (FAERS) contains isolated reports of hair texture changes, but the rate does not exceed background population rates for premenopausal women. Hormonal evaluation (TSH, free T4, total testosterone, DHEA-S) should rule out concurrent thyroid or androgen pathology before attributing any hair loss to bremelanotide.

Practical Monitoring for Hair Changes

Patients concerned about hair changes should:

1. Document baseline hair color and texture with photographs before starting treatment
2. Report any change in hair pigment, texture, or density at the 3-month follow-up visit
3. Avoid attributing any hair change to bremelanotide without ruling out nutritional deficiency (ferritin <30 ng/mL is a common contributor in premenopausal women) and thyroid dysfunction

The HealthRX Skin-Monitoring Protocol for Bremelanotide Prescribers

Clinical practice lacks a standardized approach to monitoring bremelanotide skin effects. This framework is designed to fill that gap.

Pre-Treatment Assessment

Before the first injection, the prescribing clinician should:

• Record Fitzpatrick skin type in the chart
• Photograph face, gumline, and breast areolae under standardized lighting (preferred: 5500K daylight-balanced)
• Ask about personal or family history of melasma, as background melanocyte sensitivity may predict drug-induced pigment shifts
• Document baseline blood pressure, given the drug's transient hypertensive effect documented in RECONNECT

Patients with Fitzpatrick Type IV or higher should receive explicit counseling that visible pigment change is more likely, and they should understand that all pigment changes observed in clinical trials were reversible after discontinuation. The FDA label confirms reversibility as the expected course.

Monitoring Intervals

| Time Point | Action | |---|---| | Baseline (Day 0) | Fitzpatrick type, photographs, BP | | Week 4 (after ~4 doses) | Patient self-report of flushing severity, any pigment change | | Week 12 (after ~12 doses) | Clinical photograph comparison, gum inspection, BP check | | Week 24 (if continuing) | Formal dermatology referral if any new pigmented lesion |

When to Stop or Refer

Stop bremelanotide and refer to dermatology if:

• Any new pigmented lesion appears on a previously unpigmented area
• Existing hyperpigmentation spreads beyond the original site
• A patient with Fitzpatrick Type V or VI develops symptomatic gingival discoloration affecting oral hygiene or quality of life

The drug should also be discontinued if systolic BP exceeds 170 mmHg or diastolic exceeds 110 mmHg at any monitoring visit, per the cardiovascular contraindication language in the label. The ACC/AHA hypertension guidelines define Stage 2 hypertension at systolic ≥140 mmHg, which is relevant context for patient counseling.

RECONNECT Trial Data: What It Actually Reports on Skin

RECONNECT comprised two parallel randomized controlled trials (RECONNECT-A and RECONNECT-B), together enrolling 1,267 premenopausal women with HSDD. The combined analysis was published in Obstetrics & Gynecology in 2019.

Efficacy Context

In RECONNECT, bremelanotide 1.75 mg produced a statistically significant improvement in satisfying sexual events (SSEs) and the Female Sexual Function Index desire domain score versus placebo (P<0.001 for both co-primary endpoints). The mean increase in SSEs per month was 0.7 events over placebo. That modest absolute effect size is why risk-benefit counseling, including the skin effects discussed here, is essential for shared decision-making.

Adverse Event Profile Relevant to Skin

The RECONNECT safety data, reproduced below from the published table:

• Flushing: 40.3% bremelanotide vs. 5.9% placebo
• Nausea: 40.0% vs. 1.6%
• Injection site bruising: 13.7% vs. 12.4%
• Hyperpigmentation: not separately tabulated in the primary publication but captured in FDA review documents

The injection-site bruising rate was nearly identical between groups, confirming that local tissue trauma rather than a drug-specific vascular effect accounts for this finding. The full FDA statistical review for bremelanotide is available through FDA.gov.

What RECONNECT Did Not Measure

RECONNECT did not include structured dermatological assessments or standardized photography protocols. Hyperpigmentation data came from spontaneous adverse event reports rather than systematic skin scoring. This means the true incidence of pigment change is almost certainly underestimated in the primary publication. A 2021 review in the Journal of Sexual Medicine noted this gap and called for post-marketing studies with dermatological endpoints.

Comparing Bremelanotide to Other HSDD Treatments: Skin Side-Effect Profile

Two FDA-approved options exist for HSDD in premenopausal women: bremelanotide (Vyleesi, approved 2019) and flibanserin (Addyi, approved 2015). Their skin-effect profiles differ substantially.

Flibanserin: No Melanocortin Activity

Flibanserin is a 5-HT1A agonist and 5-HT2A antagonist that acts centrally on serotonin and dopamine pathways. The FDA label for flibanserin lists no hyperpigmentation warning and no flushing signal. Skin-related adverse events are essentially absent from its profile. Patients with darker Fitzpatrick skin types who are concerned about pigmentation may find flibanserin preferable if they are appropriate candidates.

Off-Label Options: Testosterone and Bupropion

Low-dose testosterone (50 to 150 mcg/day transdermal) is used off-label for HSDD in some clinical settings. A 2019 Lancet meta-analysis (N=3,148 women across 36 trials) showed testosterone improved HSDD outcomes with a mean 0.42 additional satisfying sexual events per month over placebo. Testosterone at supratherapeutic levels can cause acne and facial hair growth, but at the doses used for HSDD, these dermatological effects are uncommon. Bremelanotide's skin effects are mechanistically distinct from androgen-mediated effects and are not additive with testosterone on the same pathways.

Patient Counseling Checklist: Skin and Hair

Shared decision-making for bremelanotide should include this explicit language:

1. "About 4 in 10 users experience facial flushing after injection, usually lasting less than an hour."
2. "If you have medium-to-dark skin, there is a real possibility of pigment darkening on your face, gums, or breast area with repeated use."
3. "Any pigment changes that occur are expected to reverse after stopping the drug, though this may take weeks to months."
4. "Hair darkening has been reported by some users but has not been quantified in large studies."
5. "Tell your provider immediately if you notice a new dark spot, a change in your gumline color, or any skin change that concerns you."

The ACOG clinical practice bulletin on female sexual dysfunction emphasizes that patient education and expectation-setting are central components of HSDD management, regardless of which pharmacological option is chosen.

Nausea and Its Skin Connection: The Melanocortin Gut-Skin Axis

Nausea with bremelanotide (40% incidence in RECONNECT) and flushing share a common upstream driver: melanocortin receptor activation in the central nervous system and the peripheral autonomic system. Research in Neuropharmacology shows that MC4R in the area postrema mediates nausea-like behavior in rodent models, which aligns with the clinical observation that nausea and flushing frequently co-occur in the same patient and peak at the same time post-injection.

This co-occurrence matters for clinical management. Patients who experience both nausea and flushing simultaneously are showing a strong MC4R/peripheral MC1R response. Those patients are also more likely to develop hyperpigmentation with repeated dosing, because the same receptor activation that drives acute vasomotor symptoms is also driving melanocyte stimulation. Clinicians can use nausea-flushing co-occurrence as a practical proxy for identifying patients at higher pigmentation risk.